{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"}]}],"title":"Platelet transfusions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}],"title":"Red blood cell transfusions"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"groups":[{"description":"GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis \\[days -4, -3, -2, -1\\] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.\n\nGCSF\n\nPlacebo","id":"OG000","title":"A. GCSF + Placebo"},{"description":"B. GCSF + meloxicam:\n\nPatients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected.\n\nGCSF\n\nmeloxicam","id":"OG001","title":"B. GCSF + Meloxicam"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number of transfusions needed were only counted among patients that underwent transplantation","reportingStatus":"POSTED","timeFrame":"Up to 6 months after transplantation ( up to 66-72 days after the start of treatment)","title":"Number of Participants That Received Red Blood Cell and Platelet Transfusions Prior to Engraftment","type":"SECONDARY","unitOfMeasure":"Participants"}